Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 16/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162759 | 0.99 | MAPKAPK2 (0.64) | MAPKAPK2ALKTLR9TLR7ADRA2A | |
| SCHEMBL4159265 | 0.89 | MAPKAPK2 (0.73) | MAPKAPK2ADRA2AADRA2BADRA2C | |
| SCHEMBL4154712 | 0.88 | MAPKAPK2 (0.72) | MAPKAPK2ADRA2AADRA2BADRA2C | |
| SCHEMBL4154340 | 0.87 | MAPKAPK2 (0.84) | MAPKAPK2ADRA2AADRA2BADRA2C | |
| SCHEMBL4147129 | 0.85 | MAPKAPK2 (0.60) | MAPKAPK2ALK | |
| SCHEMBL4138105 | 0.85 | MAPKAPK2 (0.59) | MAPKAPK2ALK | |
| SCHEMBL4151531 | 0.84 | MAPKAPK2 (0.68) | MAPKAPK2ADRA2AADRA2BADRA2C | |
| SCHEMBL4146379 | 0.84 | MAPKAPK2 (0.68) | MAPKAPK2ADRA2AADRA2BADRA2C | |
| SCHEMBL4146532 | 0.84 | MAPKAPK2 (0.67) | MAPKAPK2ALK | |
| SCHEMBL4161266 | 0.83 | MAPKAPK2 (0.68) | MAPKAPK2ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069338-A1 | Method for predicting skin sensitizing activity of compounds | DICKSON JR JOHN K | 2009-03-12 | — | — | US | disclosed |
| US-7452887-B2 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | AMPHORA DISCOVERY CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1781293-A1 | QUINOLINE- AND ISOQUINOLINE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | Amphora Discovery Corporation (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060009460-A1 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | AGRIUS GROUP, LLC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005120509-A1 | QUINOLINE- AND ISOQUINOLINE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069338-A1 | Method for predicting skin sensitizing activity of compounds | ATP5ME, ABCG2, ATP5MG | MAPKAPK2 2584/4885ALK 4809/4885TLR9 4055/4885 |
| US-20060009460-A1 | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | MAPKAPK2 3066/4885ALK 4689/4885TLR9 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.